NeuroVice Unveils PATI – A Groundbreaking Device for Seizure Management at AES Meeting

NeuroVice Launches PATI: A Game-Changer for Seizure Patients

In a significant development for epilepsy care, NeuroVice has announced that its innovative device, PATI (Protector Against Tongue Injury), is now available to the public. This groundbreaking device was unveiled at the American Epilepsy Society's annual meeting, which runs from December 5-9, 2025, in Atlanta, Georgia. NeuroVice, founded by Dr. Ashlyn Sanders, a pediatric neurology resident at Johns Hopkins University, has developed PATI with a mission to enhance the quality of life for patients enduring focal and grand-mal seizures.

Epilepsy is a widespread neurological disorder affecting approximately 65 million individuals worldwide, with around 3.4 million diagnosed in the United States alone. Each year, 45,000 children are newly diagnosed, which highlights the urgent need for better seizure management solutions. PATI is not just another medical device; it is a revolutionary tool that protects patients from oral injuries during seizures and facilitates airway management in critical situations.

Historically, emergency protocols have advised against placing objects in a patient’s mouth during a seizure, but this precaution has left one in five patients unprotected from preventable oral injuries. Without effective solutions, caregivers and first responders have resorted to using improvised items, which can exacerbate injuries. Common practices have included using wallets or dish rags, while some EMS agencies have even used bite sticks or other harmful methods that can damage teeth and cause further complications.

The introduction of PATI marks a notable shift away from outdated practices. Dr. Sanders, who has personal experience with the fear and vulnerability associated with seizures, designed PATI with the dual purpose of preventing injuries and providing secure airway access. She emphasized the importance of merging clinical insights with real patient experiences in creating a device that truly meets patient needs. "This device embodies both clinical expertise and patient experience, as it was born out of necessity," she remarked.

The design of PATI is patent-pending and addresses various safety concerns with its unique features. It includes tongue cradles to prevent biting injuries, durable bite pads to shield teeth from damage, a protective lip guard for soft tissues, and a central opening for maintaining airway access while permitting medication administration and suctioning when needed. Moreover, PATI's ergonomic handles allow for rapid and safe placement during emergency scenarios.

PATI is intended for patients aged 12 and older experiencing different types of seizures and can be used alongside existing medications for seizure management. Dr. Sanders stated that PATI not only offers mechanical protection but also represents a shift towards proactive healthcare. "The name PATI signifies its protective role and reflects our focus on the patient experience. It’s designed around the needs of those living with seizures," she explained.

Following its introduction, PATI has already piqued the interest of numerous neurologists, epilepsy specialists, and emergency medical service providers. NeuroVice CEO Jordan Schindler highlighted the device's significance, stating, "One in ten people will experience a seizure at some point in their lives. The commercial availability of PATI changes the landscape of seizure management, addressing a critical gap that has existed for generations. We transition from a reactive response to proactive care."

NeuroVice is similarly focused on educating the medical community about the new device and has set up comprehensive distribution pathways to ensure that patients and healthcare providers can access PATI easily. The device is available in the U.S. by prescription through BlinkRx, an innovative platform aiming to streamline access to necessary medications.

NeuroVice's commitment to patient-centered innovation and improved quality of care continues to resonate within the healthcare community, with support from various stakeholders including significant investors. Ultimately, the goal of NeuroVice is to redefine the standard of care for the 65 million individuals globally coping with seizure disorders, empowering both patients and healthcare providers with the tools necessary to manage seizures effectively with enhanced safety.

For more details about PATI and the company’s broader mission, interested parties are encouraged to visit NeuroVice's official website or to reach out via email to inquire about ordering.